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Anti-idiotype antibodies (anti-Id Abs) are antibodies to idiotopes
that are located in the variable region, including the antigen bind-
ing site, of another antibody. When the last is the case, these
anti-Id Abs can act as surrogates of the original antigen. The
capability of anti-Id Abs to modulate the immune response has
been the basis for the development of anti-Id vaccines against
different antigens, including tumor-associated antigens. Over the
years, its use in cancer has been demonstrated as effective and
promising. This book “Anti-idiotype antibodies in cancer treat-
ment” resumes the latest findings in the field. The book starts
with an opinion article by Gomez et al. (2012), whereas the
authors discuss amethod for prioritization of cancer antigens that
paves the way to take more rational, informed decisions in vac-
cine development. Following, we will find a number of reviews
that conform a complete updating on the subject. The first one
by Kieber-Emmons et al. (2012) explore the concept of anti-Id
Abs with its achievements and drawbacks. Following, Ladjemi
(2012) focuses on recent achievements of use of anti-Id Abs as
cancer vaccines in solid tumors. López-Requena et al. (2012)
focus on the role of anti-Id vaccination in cancer management
and on the current developments used to foster anti-idiotypic
B and T cell responses. Vázquez et al. (2012a,b) deeply analyze
the immunological mechanisms involved in the use of these anti-
bodies, while Vázquez et al. (2012a,b) focus on racotumomab,
an anti-Id vaccine already in Phase III clinical trials. Finally,
Fredriksen et al. (2012) present a hypothetical model for how
the APC-targeted vaccine molecules enhance Id-specific T and B
cells. Next, the original article of Segatori et al. (2012) conveys
preclinical research on racotumomab with or without chemother-
apy, and explores the biological role of N-glycolyl gangiosides in
a lung cancer mouse model. Two interesting clinical case studies
are also part of this book. First, Llanos et al. (2012) report a main-
tenance treatment with chemotherapy and immunotherapy in a
patient with non-small cell lung cancer. Also, Sampor et al. (2012)
present results about the immune response to racotumomab in a
child with relapsed neuroblastoma. The book closes with a very
interesting article by Gómez and Ardigo (2012), analyzing the
pharmaceutical perspective of the development of anti-Id Abs in
cancer treatment, with a fresh point of view about the relationship
between academy and industry. We as editors were very happy to
work with such an excellent group of authors, putting together a
book with good quality articles that shed light to the use of anti-
Id Abs in cancer. Likewise, we hope it constitutes to the reader
interesting material for their fields.
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